A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2018
Price : $35 *
At a glance
- Drugs ID 93 (Primary)
- Indications Pulmonary tuberculosis
- Focus Adverse reactions
- 19 Feb 2018 According to a Aeras media release, data from this study will be presented at 5th Global Forum on TB Vaccines 2018
- 07 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2014 Planned End Date changed from 1 Apr 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.